Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Fractyl Health, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company operates at the intersection of medical devices, biopharmaceuticals, and metabolic disease therapeutics, with a strategy centered on targeting the duodenum as a key regulator of glucose and metabolic dysfunction. Its approach aims to address the root causes of metabolic disease rather than solely managing symptoms.
The company’s primary business lines include an endoscopic medical device platform and a complementary biologics program designed to provide durable metabolic benefits. Fractyl Health primarily serves healthcare providers and patients within the metabolic disease treatment ecosystem, with an initial focus on populations inadequately controlled by existing pharmacologic therapies. The company positions itself uniquely by combining interventional gastroenterology with metabolic science. Fractyl Health was founded in 2010 and evolved from early research on gut-mediated metabolic signaling into a public company following its initial public offering in 2024.
Business Operations
Fractyl Health’s operations are organized around two core segments: its Revita® System medical device platform and its Rejuva™ biopharmaceutical program. The Revita® System is an endoscopic procedure designed to remodel the duodenal lining to improve insulin sensitivity and glycemic control, and it has been evaluated in multiple clinical trials. The Rejuva™ program focuses on oral and injectable biologics intended to replicate or enhance the metabolic effects observed through duodenal intervention.
The company conducts research and development primarily in the United States, with clinical trial activity extending internationally. Fractyl Health controls proprietary endoscopic technologies, clinical data, and intellectual property related to gut-based metabolic modulation. As of publicly available disclosures, the company does not report material revenue from commercialized products and remains focused on clinical development rather than product sales.
Strategic Position & Investments
Fractyl Health’s strategic direction emphasizes long-term, disease-modifying solutions for metabolic disorders, particularly for patients who do not achieve durable benefit from GLP‑1 receptor agonists or other standard therapies. Growth initiatives are centered on advancing late-stage clinical trials, expanding its biologics pipeline, and generating regulatory evidence to support potential commercialization.
The company has invested heavily in internal research and development rather than pursuing large-scale acquisitions. Its portfolio strategy prioritizes platform expansion around the duodenum’s role in metabolic signaling. Fractyl Health’s emerging technologies span interventional gastroenterology, metabolic endocrinology, and gut-based biologics. Public disclosures do not indicate material joint ventures or majority-owned operating subsidiaries beyond its core operating entity.
Geographic Footprint
Fractyl Health is headquartered in the United States, with its principal executive offices located in Massachusetts. Its operational footprint is primarily North American, where corporate management, research, and development activities are based.
Internationally, the company has conducted clinical trials and research collaborations in Europe and other select regions to support regulatory and clinical validation efforts. While it does not maintain a broad commercial presence across continents, its clinical and scientific activities give it international exposure within global metabolic disease research markets.
Leadership & Governance
Fractyl Health is led by a management team with experience across biotechnology, medical devices, and metabolic disease research. The leadership emphasizes a strategy focused on scientific rigor, long-term clinical outcomes, and addressing unmet needs in chronic metabolic disease through innovative, mechanism-driven therapies.
Key executives include:
- Harith Rajagopalan, MD, PhD – Chief Executive Officer
- Timothy Bertram, MD – Chief Medical Officer
- Andrew Daniels – Chief Financial Officer
- Mark Turco – Chief Operating Officer
- James Knight – Chief Technology Officer
The company is governed by a board of directors with backgrounds in life sciences, healthcare investing, and medical innovation, supporting oversight of clinical development, capital allocation, and corporate governance.